In previous studies, they found no correlation between these two variables; however, the studies were for a shorter period of time.1 Since the study was conducted over the first 90 days after initiating cholinesterase inhibitor therapy, it allowed the patients to titrate their baseline doses up to a tolerable and effective dose. This proposes an idea that the higher doses of cholinesterase inhibitors and length of time on these agents could be contributing to the higher risk of COPD
In previous studies, they found no correlation between these two variables; however, the studies were for a shorter period of time.1 Since the study was conducted over the first 90 days after initiating cholinesterase inhibitor therapy, it allowed the patients to titrate their baseline doses up to a tolerable and effective dose. This proposes an idea that the higher doses of cholinesterase inhibitors and length of time on these agents could be contributing to the higher risk of COPD